Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of febantel tablets in China. Welcome to wholesale bulk high quality febantel tablets for sale here from our factory. Good service and reasonable price are available.
Febantel tablets is a broad-spectrum anthelmintic based on the benzimidazole structure. functioning as a prodrug that requires hepatic metabolism within the animal to convert into bioactive derivatives such as fenbendazole and oxfendazole, thereby exerting potent anthelmintic effects. These active metabolites irreversibly inhibit the polymerization of β-tubulin within parasite cells, disrupting their microtubule system formation.
This severely interferes with the parasite's energy metabolism (e.g., glucose uptake) and cell division processes, ultimately leading to death due to nutritional depletion and physiological dysfunction. This drug exhibits high activity against both adult and larval stages of gastrointestinal nematodes.
 |
 |
Febantel COA
Its anthelmintic spectrum encompasses roundworms (e.g., Toxocara canis), hookworms (e.g., Ancylostoma caninum), trichuris (e.g., Trichuris vulpis), and certain tapeworms. It is widely used for the prevention and treatment of parasitic infections in dogs, cats, horses, cattle, and sheep. Due to its high safety profile, broad therapeutic window, and good palatability, it has become a core component in both single-ingredient and compound anthelmintic formulations in veterinary clinical practice and animal husbandry. However, it should be noted that its action is relatively slow, and its efficacy against certain developmental stages of eggs is limited.
Market Demand Driven: Dual Growth of Livestock Industry and Pet Economy
The rigid demand for large-scale livestock farming & The rise of the pet economy has given rise to an incremental market
Its anthelmintic spectrum encompasses roundworms (e.g., Toxocara canis), hookworms (e.g., Ancylostoma caninum), trichuris (e.g., Trichuris vulpis), and certain tapeworms. It is widely used for the prevention and treatment of parasitic infections in dogs, cats, horses, cattle, and sheep. Due to its high safety profile, broad therapeutic window, and good palatability, it has become a core component in both single-ingredient and compound anthelmintic formulations in veterinary clinical practice and animal husbandry. However, it should be noted that its action is relatively slow, and its efficacy against certain developmental stages of eggs is limited.
It is projected that the market demand for Fabantel within the global livestock breeding industry will reach 1.1 million tons in 2025, accounting for 25% of the overall global market share, and firmly emerge as one of the core driving forces fueling industry growth.In 2024, the total number of urban pet dogs and cats across China has surpassed 120 million. Driven by the booming pet economy, the annual sales volume of pet-specific Fabantel related products hit 390 million yuan, occupying 21.1% of the corresponding domestic market segment.
Taking "Quad Dewormer" as an example, its compound formulation contains 113.4mg of Fabantel per tablet, which can simultaneously eliminate roundworms, hookworms, tapeworms, and whipworms in dogs. The single-tablet design enhances the convenience for pet owners to take medication. It is expected that the sales volume of the pet market will exceed 450 million yuan in 2025, with a compound annual growth rate of 15%, becoming the second-largest growth pole in the industry.
Technological Innovation Leading: Compound Formulations and Formulation Upgrade
Compound formulations enhance synergistic efficacy
Fabantel is often used in combination with pimecrolimus and dihydrothiophene thiazine, forming a "triple deworming barrier":
Feabantel: Metabolized into fenbendazole, blocking the energy metabolism of parasites.
Pimecrolimus: Activates calcium channels on the surface of tapeworms, causing muscle tetanic contraction;
Dihydrothiophene thiazine: Directly paralyzes the nervous and muscle systems of roundworms.
Clinical data shows that the compound formulation has a clearance rate of over 99% for canine hookworms, roundworms, and tapeworms, significantly superior to single-drug medications.
Formulation optimization improves compliance
The market share of sustained-release tablet formulations has increased from 30% in 2020 to 42% in 2024.
Their low-frequency administration characteristics (once every 48 hours) reduce the stress response of pets.
Additionally, chewable tablets (such as Quad Dewormer Chewable) increase the active intake rate of pets to 90% by adding chicken flavoring, solving the problem of traditional tablet administration by forceful swallowing.
Policy Benefits Release: Regulatory Support and Standard Upgrade
Volume-Based Procurement and Export Incentives
In China's seventh national drug procurement round of 2024, the winning bid price for non-banther tablets dropped by 35%. However, the guaranteed procurement volume mechanism drove a 12.7% year-on-year increase in hospital prescriptions. Regarding exports, as the world's largest supplier of active pharmaceutical ingredients, China exported 1,120 tons of phentermine in 2024-a 7.1% year-on-year increase. Imports from India accounted for 36.6% of this volume, while Southeast Asian markets represented 28.4%, reflecting the ongoing expansion of international market reach.
Expansion of medical insurance catalogues and penetration at the grassroots level
Although Feabantel has not yet been included in the human medical insurance catalogue, in the veterinary field, the Ministry of Agriculture and Rural Affairs revised the "Veterinary Drug Quality Standards", tightening the residue limit standard of Feabantel from 0.5ppm to 0.2ppm, promoting the standardized development of the industry.
Challenges and Response Strategies
Risk Management of Drug Resistance
Long-term monotherapy has led to an increase in hookworm resistance to benzimidazole drugs, reaching 15% in some regions. Companies must increase R&D investment. For example, Rip Bio launched a compound injection of "Fipronil + Ivermectin" in 2024. By leveraging different mechanisms of action, it delays the emergence of resistance. Clinical validation shows its hookworm clearance rate is 22% higher than monotherapy.
Safety Controversies and Clinical Guidelines
Isolated case reports indicate fenbendazole may cause bone marrow suppression in dogs (e.g., leukopenia), though the incidence rate remains below 0.01%. The industry has controlled adverse reaction rates below 0.5% through measures such as revising product labels (adding warnings to "monitor blood counts 72 hours post-administration") and developing low-dose sustained-release formulations (e.g., 340.2mg/tablet specifications).
Future Outlook: Growth Forecast for 2025-2030
It is expected that the market size of febantel tablets in China will reach 2.13 billion yuan in 2025, and exceed 3 billion yuan in 2030, with a compound annual growth rate of 12%.
The growth drivers are:Demand side: The scale of the livestock industry has increased to 65%, and the number of pets has risen to 150 million;Supply side: The proportion of slow-release formulations exceeds 50%, and the sales proportion of compound formulations reaches 70%.
Policy side: The coverage rate of the grassroots market has exceeded 80%, and the export volume accounts for 35% of the global market share.The industry will present a "headquarters concentration + innovation-driven" pattern. Companies such as Rui Pu Bio and Kefang Bio will build competitive advantages through technological barriers, while small and medium-sized manufacturers need to focus on specialized markets (such as specialized formulations for aquatic farming) to achieve differentiated survival.
Stability: Precise Control of Environmental Factors and Degradation Pathways
The stability study of febantel tablets followed the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q1A(R2). It evaluated its degradation characteristics by simulating extreme environmental conditions (such as high temperature, light exposure, oxidation, and hydrolysis). The experiments showed that at a degradation rate of 15-20%, the main degradation products of Feabantel could be identified using liquid chromatography-mass spectrometry (LC-MS/MS), and its core degradation pathway involved:
Hydrolysis reaction: Under acidic or alkaline conditions, the ester bonds in the Fabantel molecule break, generating benzimidazole carboxylic acid derivatives. These products may affect the drug absorption efficiency;
Photolysis reaction: Ultraviolet radiation causes the sulfide bonds in the molecule to break, forming sulfoxide compounds, which may alter the drug metabolic kinetics;
Oxidation reaction: Under the action of oxidants such as hydrogen peroxide, the methyl ether groups in the molecule are oxidized to hydroxyl groups, generating more polar metabolites, which may increase the distribution volume of the drug in the body.
Studies have confirmed that Fabantel can maintain stability for 24 months under dry, light-protected, and sealed conditions (temperature ≤ 25℃, humidity ≤ 60%). Its degradation products are significantly less toxic than the parent drug and comply with international veterinary drug safety standards (such as VICH GL3(R)).
Safety of target animals: Differing responses between dogs and cats
Canine-specific hypersensitivity reaction: Although rare, some dogs may develop bone marrow suppression due to genetic susceptibility, presenting with leukopenia, thrombocytopenia, and non-regenerative anemia. For example, a 6-year-old Labrador dog experienced a complete blood cell reduction after taking Drontal Plus® (containing Fabantel 28.6mg/kg/day) for 5 consecutive days. Bone marrow biopsy confirmed bone marrow dysplasia. Such reactions may be related to the accumulation of drug metabolites (such as fenbendazole) on hematopoietic stem cells.
Feline tolerance: Cats have significantly better tolerance to Feabantel than dogs.
At the recommended dose (27.2mg/piece), even after continuous administration for 9 days, there were no significant fluctuations in hematological parameters (such as white blood cell count, platelet count), except for a mild increase in liver enzymes (ALP 196U/L) at high doses (440mg/kg/day), but it was of no clinical significance.
Safety: Dual verification from laboratory to clinical setting
Acute and chronic poisonous property assessment
Animal experiments: The acute oral poisonous property test on rats showed that the median lethal dose (LD50) of Faebantel was 1250 mg/kg (rabbit), which is a low-toxic substance; in the 90-day repeated-dose poisonous property test, rats given a continuous dose of 9000 mg/kg/day did not show significant target organ damage, proving its safety for long-term use.
Clinical research: In the dose escalation test on cats, continuous administration of 110 mg/kg/day (5 times the recommended dose) for 9 days did not cause severe adverse reactions, only mild loss of appetite was observed; while in the 220 mg/kg/day (10 times the dose) group, some animals experienced vomiting and diarrhea, but there were no deaths.
Drug interactions and contraindications
Fabantel may affect the metabolism of other drugs by inhibiting cytochrome P450 enzymes (CYP450). For example, when used in combination with phenobarbital, it may reduce the blood concentration of the latter, resulting in a weakened anti-epileptic effect. In addition, animals allergic to benzimidazole drugs should not use Fabantel. Pregnant females during the early stage (the first 45 days) should use it with caution to avoid the risk of embryotoxicity.
Risk Control: Full-chain Management from Research and Development to Use
Formulation Optimization
By encapsulating fabantel with microencapsulation technology, it can reduce gastrointestinal irritation and lower the incidence of adverse reactions such as vomiting.
Drug Monitoring
For animals that use febantel tablets for a long term, regular blood routine tests are recommended (especially for elderly dogs or those with a history of blood diseases), to detect signs of bone marrow suppression early.
Dose Adjustment
For animals with impaired liver and kidney function, the dose should be adjusted according to the endogenous creatinine clearance rate (Ccr) to avoid drug accumulation and poisonous property.
FAQ
Feabantel is a broad-spectrum benzimidazole anthelmintic compound widely used in veterinary parasitology. It features stable chemical properties and excellent oral absorption, acting as a prodrug that can be metabolized into active ingredients inside the animal body to exert powerful deworming activity against a variety of internal parasites.
Feabantel has a broad deworming spectrum, mainly effective against roundworms, tapeworms and other common gastrointestinal parasites in livestock and poultry. It can inhibit the energy metabolism of parasite cells, block nutrient absorption, and eventually lead to the death and excretion of parasites from the body, with reliable removal effect on both adult worms and larvae.
Feabantel is characterized by high efficiency, low poisonous property and good safety performance. It is suitable for conventional deworming and regular parasite prevention in cattle, sheep, pigs and other animals. It has good compatibility with most feed additives, no obvious side effects at conventional doses, and will not affect the normal growth and physiological state of livestock.
Feabantel is usually prepared into powder or oral preparation, mostly used by mixing with feed or direct oral administration according to animal body weight. It should be stored in a sealed, dry and dark environment to avoid moisture and high temperature, preventing chemical decomposition and ensuring the stability of its anthelmintic efficacy during the shelf life.
Hot Tags: febantel tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale